LLY Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of 34.4% compared to Eli Lilly & Co.'s net margin of -2.24%. Eli Lilly & Co.'s return on equity of 104.39% beat Biogen, Inc.'s return on equity of 7.36%.

Eli Lilly & Co. has a consensus price target of $1,206.07, signalling upside risk potential of 17.87%. On the other hand Biogen, Inc. has an analysts' consensus of $205.52 which suggests that it could grow by 7%. Given that Eli Lilly & Co. has higher upside potential than Biogen, Inc., analysts believe Eli Lilly & Co. is more attractive than Biogen, Inc..

Eli Lilly & Co. has a beta of 0.388, which suggesting that the stock is 61.171% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.160, suggesting its less volatile than the S&P 500 by 84.033%.

Eli Lilly & Co. has a quarterly dividend of $1.73 per share corresponding to a yield of 0.61%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly & Co. pays 26.14% of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $19.3B, which are larger than Biogen, Inc. quarterly revenues of $2.2B. Eli Lilly & Co.'s net income of $6.6B is higher than Biogen, Inc.'s net income of -$48.9M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 45.30x while Biogen, Inc.'s PE ratio is 21.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 14.30x versus 2.96x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 34.4% compared to Eli Lilly & Co.'s net margin of -121.83%. Eli Lilly & Co.'s return on equity of 104.39% beat Moderna, Inc.'s return on equity of -29.19%.

Eli Lilly & Co. has a consensus price target of $1,206.07, signalling upside risk potential of 17.87%. On the other hand Moderna, Inc. has an analysts' consensus of $41.75 which suggests that it could fall by -16%. Given that Eli Lilly & Co. has higher upside potential than Moderna, Inc., analysts believe Eli Lilly & Co. is more attractive than Moderna, Inc..

Eli Lilly & Co. has a beta of 0.388, which suggesting that the stock is 61.171% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Eli Lilly & Co. has a quarterly dividend of $1.73 per share corresponding to a yield of 0.61%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly & Co. pays 26.14% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $19.3B, which are larger than Moderna, Inc. quarterly revenues of $678M. Eli Lilly & Co.'s net income of $6.6B is higher than Moderna, Inc.'s net income of -$826M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 45.30x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 14.30x versus 9.95x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 34.4% compared to Eli Lilly & Co.'s net margin of 21.74%. Eli Lilly & Co.'s return on equity of 104.39% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Eli Lilly & Co. has a consensus price target of $1,206.07, signalling upside risk potential of 17.87%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 10.95%. Given that Eli Lilly & Co. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Eli Lilly & Co. is more attractive than Regeneron Pharmaceuticals, Inc..

Eli Lilly & Co. has a beta of 0.388, which suggesting that the stock is 61.171% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Eli Lilly & Co. has a quarterly dividend of $1.73 per share corresponding to a yield of 0.61%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.94 per share. Eli Lilly & Co. pays 26.14% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $19.3B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Eli Lilly & Co.'s net income of $6.6B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 45.30x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 14.30x versus 5.93x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 34.4% compared to Eli Lilly & Co.'s net margin of --. Eli Lilly & Co.'s return on equity of 104.39% beat Viking Therapeutics, Inc.'s return on equity of -46.41%.

Eli Lilly & Co. has a consensus price target of $1,206.07, signalling upside risk potential of 17.87%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $92.72 which suggests that it could grow by 198.14%. Given that Viking Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Viking Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Eli Lilly & Co. has a beta of 0.388, which suggesting that the stock is 61.171% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.489%.

Eli Lilly & Co. has a quarterly dividend of $1.73 per share corresponding to a yield of 0.61%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly & Co. pays 26.14% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $19.3B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Eli Lilly & Co.'s net income of $6.6B is higher than Viking Therapeutics, Inc.'s net income of -$157.7M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 45.30x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 14.30x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.